{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:12:56Z","timestamp":1790230376070,"version":"4.1.0"},"reference-count":56,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T00:00:00Z","timestamp":1516838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bristol-Myers Squibb"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2018,4,15]]},"abstract":"<jats:p>\n                    Chronic myeloid leukemia (CML) has evolved into a chronic disease that is managed with tyrosine kinase inhibitor therapy. Now that long\u2010term survival has been achieved in patients with CML, the focus of treatment has shifted to dose optimization, with the goal of maintaining response while improving quality of life. In this review, the authors discuss optimizing the dose of the second\u2010generation tyrosine kinase inhibitor dasatinib. Once\u2010daily dosing regimens for dasatinib in the first and later lines of treatment were established through long\u2010term (5\u2010year and 7\u2010year) trials. Recently published data have indicated that further dose optimization may maintain efficacy while minimizing adverse events. Results obtained from dose optimization and discontinuation trials currently in progress will help practitioners determine the best dose and duration of dasatinib for patients with CML, because treatment decisions will be made through continued discussions between physicians and patients.\n                    <jats:bold>\n                      <jats:italic>Cancer<\/jats:italic>\n                      2018;124:1660\u201072\n                    <\/jats:bold>\n                    . \u00a9 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution\u2010NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.\n                  <\/jats:p>","DOI":"10.1002\/cncr.31232","type":"journal-article","created":{"date-parts":[[2018,4,9]],"date-time":"2018-04-09T12:55:21Z","timestamp":1523278521000},"page":"1660-1672","source":"Crossref","is-referenced-by-count":29,"title":["Dasatinib dose management for the treatment of chronic myeloid leukemia"],"prefix":"10.1002","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3361-3981","authenticated-orcid":false,"given":"Moshe","family":"Talpaz","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine University of Michigan Cancer Center Ann Arbor Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences University of Turin, San Luigi Hospital Orbassano\u2010Torino Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab","family":"Atallah","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Medical College of Wisconsin Milwaukee Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Versailles Medical Center, INSERM UMR 1173 University of Versailles Saint\u2010Quenti\u2010en\u2010Yvelines Paris Saclay Le Chesnay France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,25]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00048-4"},{"key":"e_1_2_5_6_1","unstructured":"SEER Stat Fact Sheets: Chronic myeloid leukemia (CML).Statistics at a Glance.https:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html. Accessed May 31 2016."},{"key":"e_1_2_5_7_1","volume-title":"Sprycel (dasatinib) [prescribing information]","year":"2017"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-11-167"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-347575"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24423"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"e_1_2_5_12_1","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1182\/blood.V124.21.4537.4537","article-title":"Management of adverse events associated with dasatinib during early periods of therapy in the treatment of chronic myeloid leukemia\u2010a clinical report of Daria\u201001 Study [abstract]","volume":"124","author":"Mizuta S","year":"2014","journal-title":"Blood."},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12423"},{"key":"e_1_2_5_14_1","first-page":"85","article-title":"Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure\u2010response analysis of a Phase III study","volume":"5","author":"Wang X","year":"2013","journal-title":"Clin Pharmacol."},{"issue":"1","key":"e_1_2_5_15_1","first-page":"237","article-title":"Dasatinib daily dose optimization based on residual drug levels resulted in reduced risk of pleural effusions and high molecular response rates: final results of the randomized OPTIM DASATINIB trial [abstract]","volume":"99","author":"Rousselot P","year":"2014","journal-title":"Haematologica."},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1769-2"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08245.x"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.12604"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.3727\/096504015X14452563485986"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-015-0258-1"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_2_5_23_1","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Chronic Myelogenous Leukemia, version 2.2018","author":"National Comprehensive Cancer Network","year":"2017"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.01.003"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1968-y"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.4999\/uhod.12004"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-016-2155-y"},{"key":"e_1_2_5_29_1","unstructured":"Kanto CML Study Group.Phase II Clinical Trial of Low Dose Dasatinib in Patients With Resistant or Intolerant Chronic Myeloid Leukemia Who Are Treated With Low Lose Imatinib. World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) ID: JPRN\u2010UMIN000003499.http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN\u2010UMIN000003499. Accessed April 1 2016."},{"key":"e_1_2_5_30_1","unstructured":"Australian New Zealand Clinical Trials Registry (ANZCTR).The DIRECT study: Individualised Dasatinib Dosing for Elderly Patients With Chronic Myelogenous Leukaemia. ID: ACTRN12616000738426.https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12616000738426. Accessed March 6 2017."},{"key":"e_1_2_5_31_1","unstructured":"ClinicalTrials.gov.De\u2010Escalation and Stopping Treatment of Imatinib Nilotinib or sprYcel in Chronic Myeloid Leukaemia (DESTINY).ClinicalTrials.govidentifier: NCT01804985.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01804985?term=NCT01804985&rank=1. Accessed May 30 2016."},{"key":"e_1_2_5_32_1","unstructured":"ClinicalTrials.gov.Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib.ClinicalTrials.govidentifier: NCT02689440.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02689440?term=NCT02689440&rank=1. Accessed March 27 2016."},{"key":"e_1_2_5_33_1","unstructured":"European Leukemia Trial Registry.Dasatinib Holiday for Improved Tolerability (DasaHit). European Leukemia Trial Registry Id KN\/ELN: LN_CMLSTU_2015_576.http:\/\/www.leukemia\u2010net.org\/trial\/en\/detail_trial.html?id=576. Accessed March 31 2016."},{"key":"e_1_2_5_34_1","unstructured":"ClinicalTrials.gov.Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients \u226560 Years in Deep Molecular Response.ClinicalTrials.govidentifier: NCT02326311.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02326311?term=NCT02326311&rank=1. Accessed March 27 2016."},{"key":"e_1_2_5_35_1","unstructured":"ClinicalTrials.gov.Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib (DasPAQT).ClinicalTrials.govidentifier: NCT02348957.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02348957?term=DasPAQT&rank=1. Accessed March 27 2016."},{"key":"e_1_2_5_36_1","unstructured":"World Health Organization International Clinical Trials Registry Platform.Epidemiological and Clinical Research Information Network. A phase 2 study of mid\u2010term compliance and effectiveness of dasatinib therapy in patients with chronic myeloid leukemia. 2012. World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) ID: JPRN\u2010UMIN000007345.http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN\u2010UMIN000007345. Accessed April 12 2017."},{"key":"e_1_2_5_37_1","unstructured":"ClinicalTrials.gov.OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy) (OPTIM DASATINIB).ClinicalTrials.govidentifier: NCT01916785.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01916785. Accessed March 27 2016."},{"key":"e_1_2_5_38_1","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood.V120.21.916.916","article-title":"Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)\u2010chronic myeloid leukemia (CML) patients with stable undetectable BCR\u2010ABL transcripts [abstract]","volume":"120","author":"Rea D","year":"2012","journal-title":"Blood."},{"issue":"1","key":"e_1_2_5_39_1","first-page":"230","article-title":"Attempt to early discontinue dasatinib first line in chronic phase CML patients in early molecular response and included in the prospective OPTIM\u2010DASATINIB trial [abstract]","volume":"100","author":"Rousselot P","year":"2015","journal-title":"Haematologica."},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00196-9"},{"key":"e_1_2_5_41_1","unstructured":"ClinicalTrials.gov.Open\u2010Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response (DASFREE).ClinicalTrials.govidentifier: NCT01850004.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01850004?term=NCT01850004&rank=1. Accessed June 2 2016."},{"key":"e_1_2_5_42_1","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1182\/blood.V128.22.1895.1895","article-title":"Treatment\u2010free remission (TFR) in patients with chronic phase chronic myeloid leukemia (CML\u2010CP) and in stable deep molecular response (DMR) to dasatinib\u2010the Dasfree Study [abstract]","volume":"128","author":"Shah NP","year":"2016","journal-title":"Blood."},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-742205"},{"key":"e_1_2_5_44_1","unstructured":"ClinicalTrials.gov.Dasatinib for Patients Achieving Complete Molecular Response for Cure (D\u2010NewS Trial).ClinicalTrials.govidentifier: NCT01887561.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01887561?term=NCT01887561.&rank=1. Accessed January 27 2017."},{"key":"e_1_2_5_45_1","unstructured":"ClinicalTrials.gov.Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia\u2010CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial.ClinicalTrials.govidentifier: NCT01627132.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01627132?term=Discontinuation+of+Dasatinib+in+Patients+With+Chronic+Myeloid+Leukemia\u2010CP+Who+Have+Maintained+Complete+Molecular+Remission+for+Two+Years%3B+Dasatinib+Stop+Trial&rank=1. Accessed March 6 2017."},{"key":"e_1_2_5_46_1","unstructured":"ClinicalTrials.gov.Front\u2010line Treatment of BCR\u2010ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib (CML1113).ClinicalTrials.govidentifier: NCT01761890.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01761890?term=NCT01761890&rank=1. Accessed May 30 2016."},{"key":"e_1_2_5_47_1","unstructured":"ClinicalTrials.gov.The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study).ClinicalTrials.govidentifier: NCT02269267.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02269267?term=NCT02269267&rank=1. Accessed May 24 2016."},{"key":"e_1_2_5_48_1","unstructured":"ClinicalTrials.gov.Treatment\u2010free Remission Accomplished With Dasatinib in Patients With CML (TRAD).ClincalTrials.govidentifier: NCT02268370.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02268370?term=TRAD&rank=1. Accessed March 27 2016."},{"key":"e_1_2_5_49_1","unstructured":"ClinicalTrials.gov.European Stop Tyrosine Kinase Inhibitor Study (EURO\u2010SKI).ClinicalTrials.govidentifier: NCT01596114.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01596114?term=European+Stop+Tyrosine+Kinase+Inhibitor+Study&rank=1. Accessed January 27 2017."},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12892"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23902"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117473"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.974047"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.11.001"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"e_1_2_5_56_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2016-0012"},{"key":"e_1_2_5_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-015-0665-0"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.31232","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.31232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T16:26:15Z","timestamp":1760286375000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.31232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,25]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,4,15]]}},"alternative-id":["10.1002\/cncr.31232"],"URL":"https:\/\/doi.org\/10.1002\/cncr.31232","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,25]]}}}